It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
The partnership is a significant step in delivering advanced cancer therapies to patients.
Subscribe To Our Newsletter & Stay Updated
